ZTS · Full Picture

Zoetis Inc. — the full picture

Earnings window · 2026-07-16 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Convertible Senior Notes · Debt, leverage & refinancingPriority 76
    -13.3% liability (realized); structured_verified
    On December 18, 2025 Zoetis completed a private offering of 0.250% convertible senior notes with an aggregate principal amount of $2.0 billion and a maturity date of June 15, 2029.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 75
    +123.9% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Non-GAAP adjusted net income for the six months ended June 30, 2026 was $1,427 million.
  3. Liquidity and Debt Position · Debt, leverage & refinancingPriority 74
    -12.4% cash (realized); structured_verified
    Net cash used in financing activities was $1,653 million for the six months ended June 30, 2026, compared with $1,241 million for the six months ended June 30, 2025.
  4. Capital Return Program · Buybacks & dividendsPriority 72
    -10.2% cash (realized); structured_verified
    Following the offering, Zoetis used $1,535 million of proceeds for additional repurchases of 12.3 million shares which were completed as of March 31, 2026, and as of June 30, 2026 there was $1.3 billion remaining under the $6 billion authorization.
  5. Long-term Debt Issuance · Debt, leverage & refinancingPriority 72
    -8.9% cash (realized); structured_verified
    On August 18, 2025 Zoetis issued $850 million aggregate principal amount of 4.150% senior notes due 2028 and $1.00 billion aggregate principal amount of 5.000% senior notes due 2035, with an original issue discount of $2 million.
  6. International Segment Growth · UnclassifiedPriority 68
    +13.8% revenue (realized); structured_verified
    International segment revenue increased by $252 million, or 12%, in the six months ended June 30, 2026 versus the six months ended June 30, 2025; operational revenue increased by $141 million, or 7%.
  7. Competition and Pricing Pressure · Competition & market sharePriority 64
    3 sources (news, press_release, sec_filing); quote_verified
    Companion animal revenue decline in the U.S. was primarily due to softer end-market demand and heightened competitive pressure on the key dermatology franchise and Simparica Trio, impact of generic competition on Cerenia and Convenia, and lower sales of Librela.
  8. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 62
    -5.2% net_income; 1 forward row(s); quote_verified
    Full-year 2026 certain significant items and acquisition and divestiture-related costs are expected to be approximately $150 (prior guidance approximately $100).
  9. Revolving Credit Facility · Debt, leverage & refinancingPriority 62
    1 forward row(s); quote_verified
    In August 2025, Zoetis entered into a $1.25 billion senior unsecured revolving credit facility that expires in August 2030 and can be increased to up to $1.75 billion subject to certain conditions.
  10. Guidance / Outlook · Guidance & outlookPriority 59
    2 sources (news, press_release); 2 forward row(s); quote_verified
    Revised full-year 2026 revenue guidance: $9.120 billion to $9.320 billion (organic operational growth of (3)% to (1)%).
  11. Macroeconomic Consumer Pressure · Macroeconomic conditionsPriority 58
    quote_verified
    Quarterly financial results are subject to variability including tariffs and other trade protection measures, the decline in global macroeconomic conditions, competitive dynamics, geopolitical tensions, inflation, global supply chain disruption and supply availability, variability in distributor inventory stocking levels, weather patterns, herd management decisions, regulatory actions, disease outbreaks, product and geographic mix, timing of price increases and customer expectations, timing of investment decisions and operational and other changes made in connection with the change in accounting principle to eliminate the one-month financial reporting lag in 2026 for our subsidiaries operating outside the U.S.
  12. Headcount / Restructuring · Restructuring & impairmentPriority 57
    2 sources (press_release, sec_filing); quote_verified
    Three months ended June 30, 2026 restructuring charges and certain acquisition and divestiture-related costs: $77 million (three months ended June 30, 2025: $30 million).

Threads by pillar

Revenue & Demand Priority 87 · 6 threads

Costs & Margins Priority 76 · 5 threads

Capital & Balance Sheet Priority 94 · 7 threads

Strategy & Portfolio Priority 67 · 2 threads

Legal, Regulatory & Policy Priority 45 · 2 threads

Guidance & Outlook Priority 59 · 1 thread

Macro & Market Conditions Priority 77 · 6 threads

Management & Governance Priority 40 · 3 threads

Unclassified Priority 73 · 2 threads

Expected impact by metric

metricforward netforward grossrealized
net_income-5.2%+5.2%-3.6%
operating_income+1.2%+1.2%+11.3%
margin-0.4%+0.4%-0.9%
cash——-18.7%
assets——-0.9%
revenue——+134.0%
liability——-16.7%